18 February 2021
blog
10 February 2021
Adjuvant Leads $6 million Series B for Frontier Nutrition
Read Article
22 January 2021
MinervaX Raises Upsized €47.4 Million Series B for Novel GBS Vaccine Candidate
Read Article
26 October 2020
The Power Of Choice
Read Article
25 August 2020
Henry Ford Didn’t Invent the Assembly Line
Read Article
25 August 2020
Rabies Restock
Read Article
18 June 2020
Let’s Do More With Less
Read Article
26 May 2020
The Platform That Was Promised
Read Article
11 May 2020
Perfecting Detecting
Read Article
14 April 2020
Genomics’ Missing Puzzle Piece
Read Article
20 March 2020
Adjuvant Adds Third COVID-19 Intervention to its Portfolio
Read Article
13 February 2020
Codagenix Teams Up with World’s Largest Vaccine Manufacturer to Mount a COVID-19 Response
Read Article
30 January 2020
Deoptimize This
Read Article
13 January 2020
Adjuvant Leads $20 Million Series B for Codagenix, Inc.
Read Article
21 November 2019
Melioidosis: Ever Heard of it?
Read Article
18 September 2019
Reprogramming a 50-Year-Old Vaccine to Tackle a Sprawling List of Modern Diseases
Read Article
10 September 2019
Bringing Biologic Potency Testing into the 21st Century
Read Article
23 July 2019
“Beating Herpes”: Adjuvant’s First Investment Targets a Daunting Viral Infection
Read Article
04 June 2019
CEPI Awards up to US$21 million to Themis Bioscience for Phase 3 Chikungunya Vaccine Development
Read Article
15 May 2019
Lilly deSouza Burr Joins the Adjuvant Capital Team in New York
Read Article
01 October 2018